Respiratory Support in Severe Chronic Obstructive Pulmonary Disease Exacerbation

Comparison of High Flow Nasal Cannula, Noninvasive Positive Ventilation (NPPV) and Invasive Positive Ventilation (IPPV) in Severe Chronic Obstructive Pulmonary Disease Exacerbation (AECOPD)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03020394

Enrollment

208

Registered

2017-01-13

Start date

2017-01-31

Completion date

2020-12-31

Last updated

2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation

Keywords

COPD Exacerbation, Noninvasive Positive Ventilation, Invasive Positive Ventilation, severe, High flow nasal cannula

Brief summary

Preliminary studies have shown that NPPV can avoid tracheal intubation in 40% to 60% patients who have severe exacerbation of COPD. Recently, large-scale comparative effectiveness research (CER) also found that compared with invasive ventilation, NPPV can reduce mortality rates. But there's no high-quality clinical studies which can confirm this. Therefore, investigators believe that NPPV can avoid intubation in patients with severe exacerbation of COPD in ICU with perfect monitoring conditions and reasonable human resource allocation, in order to reduce IMV-related complications and improve patients' outcomes.

Detailed description

In part of the patients who were AECOPD with pH \<7.25 , preliminary studies have shown that NPPV can avoid tracheal intubation in 40% to 60% patients, and also reduce the incidence of VAP. Recently, large-scale comparative effectiveness research (CER) also found that compared with invasive ventilation, NPPV can reduce mortality rates. At present, there's no high-quality clinical studies which can confirm this, and clinical guidelines do not have a recommendation on the use of NPPV in these patients. Therefore, investigators believe that NPPV can avoid intubation in patients with severe exacerbation of COPD in ICU with perfect monitoring conditions and reasonable human resource allocation, as well as the progress of medical technology in NPPV in recent years, in order to reduce IMV-related complications and improve patients' outcomes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* AECOPD;

Exclusion criteria

* refuse to engage in the study; * have been included in other study.

Design outcomes

Primary

Measure	Time frame
The incidence of ventilator-associated pneumonia (VAP)	90days
The all cause mortality of ICU and hospitalization	90 days

Secondary

Measure	Time frame
The length of stay of ICU and hospitalization	90 days
The length of stay of mechanical ventilation	90 days

Countries

China

Contacts

Primary ContactJingen Xia, Master

xiajingen_00632@163.com13466396561

Outcome results